[18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: Results of the German multicentre trial

Annals of Oncology

Volumn 19, Issue 9, 2008, Pages 1619-1623

  de Wit, Maike ^a,n   Brenner, W ^a   Hartmann, M ^b   Kotzerke, J ^c   Hellwig, D ^d   Lehmann, J ^e   Franzius, C ^f   Kliesch, S ^f   Schlemmer, M ^g   Tatsch, K ^g   Heicappell, R ^h   Geworski, L ⁱ   Amthauer, H ⁱ   Dohmen, B M ^j   Schirrmeister, H ^k   Cremerius, U ^l   Bokemeyer, C ^a   Bares, R ^m  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b German Military Hospital Hamburg   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

^e SAARLAND UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^g UNIVERSITY OF MUNICH   (Germany)

^h Department of Urology   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j Department of Nuclear Medicine   (Germany)

^k UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^l KLINIKUM INGOLSTADT   (Germany)

^m UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

ⁿ VIVANTES KLINIKUM NEUKÖLLN   (Germany)

more..

Author keywords

FDG PET; Germ cell tumour; NSGCT; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GERMANY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NON SEMINOMATOUS GERMINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TUMOR VOLUME;

ADOLESCENT; ADULT; FLUORODEOXYGLUCOSE F18; GERMANY; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TESTICULAR NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 45849134979     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn170     Document Type: Article

References (16)

1. Leibovitch L, Foster RS, Kopecky KK et al. Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell tumor using size criteria of retroperitoneal lymph nodes. J Urol 1995; 154: 1759-1763.
2. Smith TAD. FDG uptake, tumor characteristics and response to therapy: A review. Nucl Med Commun 1998; 1: 97-105.
3. Higashi T, Sakahara H, Torizuka T et al. Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET. J Nucl Med 1999; 40: 1424-1433.
4. Kinkel K, Lu Y, Both M et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): A meta-analysis. Radiology 2002; 224: 748-756.
5. Valk PE, Abella-Columna E, Haseman MK et al. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999; 134: 503-511.
6. Kern KA, Brunetti A, Norton JA et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 1988; 29: 181-186.
7. Newman JS, Francis IR, Kaminski MS. Imaging of lymphoma with PET with 2-(F-18)-fluoro-2-deoxy-D-glucose: Correlation with CT. Radiology 1994; 190: 111-116.
8. Dewan NA, Gupta NC, Redepenning LS et al. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules: Potential role in evaluation and management. Chest 1993; 104: 997-1002.
9. de Wit M, Bumann D, Beyer W et al. Whole-body positron-emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 1997; 8: 57-60.
10. Geworski L, Knoop BO, de Wit M et al. Multicenter comparative evaluation of calibration and cross calibration of positron emission tomographs. J Nucl Med 2002; 43: 635-639.
11. Minn H, Leskinen-Kallio S, Lindholm P et al. (18-F)Fluorodeoxyglucose uptake in tumors: Kinetic vs. steady-state methods with reference to plasma insulin. J Comput Assist Tomogr 1993; 17: 115-123.
12. Mostofi FK, Sesterhenn IK. Revised international classification of testicular tumors. In Jones WG, Harnden P, Appleyard I (eds): Germ Cell Tumors III. Advances in the Biosciences, Volume 9. Oxford, UK: Pergamon Press 1994; 153-158.
13. Albers P, Bender H, Yilmaz H et al. Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors. Urology 1999; 53: 808-811.
14. Spermon JR, De Geus-Oei LF, Kiemeney LA et al. The role of (18)-fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumors. BJU Int 2002; 89: 549-556.
15. Lassen U, Daugaard G, Eigtved A et al. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumors. Eur J Nucl Med 2003; 30: 396-402.
16. 18Fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22 - the NCRI Testis Tumour Clinical Study Group. J Clin Oncol 2007; 25: 3090-3095.